Skip to main content
Indegene Limited logo

Indegene Limited — Investor Relations & Filings

Ticker · INDGN ISIN · INE065X01017 LEI · 335800XFEREFIW9LG995 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2024-10-28 Earnings Release
Country IN India
Listing BSE.NS INDGN

About Indegene Limited

https://www.indegene.com/

Indegene Limited provides digital-led commercialization services for the life sciences sector. The company integrates deep domain knowledge with proprietary technology platforms to assist biopharmaceutical, emerging biotech, and medical device organizations. Its core offerings span the entire product lifecycle, including clinical development support, regulatory compliance, pharmacovigilance, and multi-channel marketing operations. By leveraging artificial intelligence and machine learning, Indegene enables clients to optimize drug development processes, enhance patient engagement, and drive operational efficiencies. The company focuses on modernizing traditional commercial models through data-driven insights and digital transformation strategies, helping global healthcare organizations navigate complex regulatory environments and improve health outcomes through scaled, technology-enabled solutions.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 28, 2024, announcing the financial results for the quarter ended September 30, 2024. It includes key financial highlights such as revenue, profit after tax, margins, and growth percentages. The document explicitly states it is a press release and provides summarized financial results rather than detailed financial statements or comprehensive analysis. The length is 4394 characters, which is relatively short and typical for an earnings release announcement. There is no indication that this is a full interim or quarterly report containing detailed financial statements and analysis. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2024-10-28 English
Outcome of Board Meeting
Regulatory Filings
2024-10-28 English
Financial Result Updates
Regulatory Filings
2024-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a formal letter addressed to stock exchanges announcing the scheduling of an earnings call for Q2FY25. It includes details such as the date and time of the call, speakers (CEO and CFO), and dial-in information. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to disclosure of material events. The content is an announcement of an upcoming earnings call, not the transcript or the earnings release itself. The document length is short (1879 characters), and it serves to inform stakeholders about the call rather than provide financial results or analysis. Therefore, it fits the category of a Call Transcript announcement or invitation, but since it is not the transcript itself, it is best classified as a Call Transcript (CT) type document, as per the definitions, this is the closest match for an earnings call announcement. However, the definitions specify CT as the full transcript, and this is an announcement of the call. Given the options, the best fit is Call Transcript (CT) because it relates directly to the earnings call event. Confidence is high due to clear mention of earnings call details and regulatory reference.
2024-10-22 English
Board Meeting — INDEGENE LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half…
Regulatory Filings
2024-10-22 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification of a scheduled Board Meeting to consider and approve unaudited consolidated and standalone financial results for the quarter ended September 30, 2024. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document does not contain the financial results themselves but informs about the upcoming board meeting where these results will be approved. The document length is short (1843 characters) and serves as an announcement rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release, which would require actual financial data or results.
2024-10-22 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.